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Edited by Sandro SonninoAbstract Ins(1,4,5,6)P4, a biologically active cell constituent,
was recently advocated as a substrate of human Ins(3,4,5,6)P4
1-kinase (hITPK1), because stereochemical factors were believed
relatively unimportant to speciﬁcity [Miller, G.J., Wilson, M.P.,
Majerus, P.W. and Hurley, J.H. (2005) Speciﬁcity determinants
in inositol polyphosphate synthesis: crystal structure of inositol
1,3,4-triphosphate 5/6-kinase. Mol. Cell. 18, 201–212]. Con-
trarily, we provide three examples of hITPK1 stereospeciﬁcity.
hITPK1 phosphorylates only the 1-hydroxyl of both Ins(3,5,6)P3
and the meso-compound, Ins(4,5,6)P3. Moreover, hITPK1 has
>13,000-fold preference for Ins(3,4,5,6)P4 over its enantiomer,
Ins(1,4,5,6)P4. The biological signiﬁcance of hITPK1 being
stereospeciﬁc, and not physiologically phosphorylating Ins
(1,4,5,6)P4, is reinforced by our demonstrating that
Ins(1,4,5,6)P4 is phosphorylated (Km = 0.18 lM) by inositol-
phosphate-multikinase.
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Inositol phosphates comprise a large family of intracellular
signals which play many important roles in cell biology
[1–3]. These biological actions can be quite speciﬁc to one partic-
ular inositol phosphate. For example, Ins(3,4,5,6)P4 is the only
naturally occurring inositol phosphate that can inhibit the con-
ductance of CaMKII-activated Cl channels [4].
In contrast, some of the enzymes that metabolize inositol
phosphates can be relatively promiscuous [5]. For example,
mammalian ITPK1 phosphorylates Ins(1,3,4)P3 at both the
5- and 6-positions [6,7] while also acting as a physiologically
reversible Ins(3,4,5,6)P4 1-kinase and Ins(1,3,4,5,6)P5 1-phos-
phatase [8,9]. This enzyme, by determining cellular Ins
(3,4,5,6)P4 levels, regulates cellular Cl
 channel activities
[4]. One explanation for the catalytic versatility of ITPK1
[8] is based on a long-standing hypothesis [10] that recog-
nizes that some inositol phosphates may interact with the*Corresponding author. Fax: +1 919 541 0559.
E-mail address: shears@niehs.nih.gov (S.B. Shears).
0014-5793/$32.00 Published by Elsevier B.V. on behalf of the Federation of
doi:10.1016/j.febslet.2005.12.016binding sites of receptors and enzymes in more than one ori-
entation (i.e., ‘‘mode’’), enabling one inositol phosphate to
mimic another by presenting to the docking site some key
recognition features. These determinants of ligand binding
are typically considered not to be restricted to the two-
dimensional arrangement of phosphates and hydroxyls
around the inositol ring, but also to include the three-dimen-
sional stereochemistry at each position of the ring. Thus, our
model for ligand binding to ITPK1 is stereochemically
based, and it proposes that the enzyme uses three diﬀerent
binding modes [8] (Fig. 1): Mode 1 binding (permitting 1-ki-
nase activity) was designated for Ins(3,4,5,6)P4. We further
proposed that Ins(1,3,4)P3 could bind to the active site in
two orientations, designated mode 2 (permitting 6-kinase
activity) and mode 3 (permitting 5-kinase activity). Mode 3
also accounts for the 5-hydroxyl phosphorylation of the
non-physiological substrate, Ins(1,2,4)P3 [11]. Three substitu-
ents on the inositol ring (groups coloured red in Fig. 1), are
common to each binding mode, but by themselves, these are
insuﬃcient to fully deﬁne ligand speciﬁcity, since all three
groups are also present on Ins(1,4)P2, which is not a sub-
strate [8,12]. We therefore proposed that ligand recognition
is combinatorial in nature, with some groups making addi-
tional contributions, but only in speciﬁc binding modes [8].
This model for ligand binding suggests that ITPK1 might
be one of those proteins [13] that utilizes both rigid and ﬂex-
ible regions in its active site.
Eﬀorts to test our predictions by determining the crystal
structure of the human ITPK1 (hITPK1) have so far not
been successful (G. Miller, J. Hurley and S. Shears, unpub-
lished data). It was therefore a substantial advance when
Miller et al. [14] recently solved the structure of the ITPK1
homologue which is present in Entamoeba histolytica. This
enabled the modeling of the structural determinants of ligand
speciﬁcity for the amoeboid enzyme. Miller et al. [14] also
comprehensively conﬁrmed the nature of the active site of
the human enzyme by site-directed mutagenesis, so they ap-
plied their ligand-binding model to hITPK1. This model
[14] has the same three binding modes that we [8] originally
put forward for Ins(3,4,5,6)P4, Ins(1,3,4)P3 and Ins(1,2,4)P3,
but their hypothesis [14] still diﬀers from ours in two key as-
pects. First, in order to rationalize the phosphorylation of
Ins(1,3,4)P3 at both the 5- and 6-hydroxyl, both of theseEuropean Biochemical Societies.
Fig. 1. Two models of the structural determinants of ligand speciﬁcity
for hITPK1. The ﬁgure depicts in column a our earlier proposal that
there are three modes of binding of inositol phosphates to hITPK1 [8].
It can be illuminating to consider these diﬀerent binding modes (i.e.,
‘‘1’’, ‘‘2’’ and ‘‘3’’) as permitting 1-kinase, 6-kinase and 5-kinase
activities, respectively. These phosphorylation sites are marked with a
yellow circle. Three groups in Ins(3,4,5,6)P4, Ins(1,3,4)P3 and
Ins(1,2,4)P3 (coloured red) are conserved in all three of these proposed
binding modes. We have previously noted that these groups by
themselves are insuﬃcient to designate substrate speciﬁcity, so we have
proposed a combinatorial recognition model in which some of the
additional groups (coloured green) contribute to ligand recognition in
a mode-speciﬁc manner [8]. Miller et al. [14] have put forward a
simpler, but more promiscuous version of this model (column b) in
which stereochemical factors are not signiﬁcant determinants of ligand
binding. Although this model developed primarily from experiments
with ITPK1 from Entamoeba histolytica, it was proposed to be also
applicable to hITPK1. They proposed that, irrespective of stereo-
chemistry, substrate speciﬁcity was determined by the presence of
phosphates at sites C, D and F and not at sites A and B; in this
model, either (but not both) of the hydroxyl groups can be phosphor-
ylated. Position E was considered unimportant. N/A, not applicable
(i.e., model b does not accept that Ins(1,3,4)P3 can bind in this
orientation). See text for further details.
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c-phosphate of ATP that either (but not both) could be phos-
phorylated by direct inline transfer [14]. In that context, only
one binding mode is necessary in order to explain the two
products of Ins(1,3,4)P3 phosphorylation (equivalent to our
mode 2; Fig. 1).
A second, and unique aspect of the model of Miller et al.
[14] is the proposal that, for the amoeboid ITPK1, ligand
speciﬁcity is not signiﬁcantly aﬀected by either the hydroxyl
groups, nor by their orientation (i.e., axial vs. equatorial),
nor by the stereochemistry at any of the six stereogenic cen-
tres of the inositol ring (Fig. 1). In the current study, we
have investigated to what extent these observations mightalso apply to hITPK1. We were also intrigued by the range
of additional inositol phosphates that Miller et al. [14] pro-
posed were metabolized by both the amoeboid and human
ITPK1. Most of these additional inositol phosphates are
not constituents of mammalian cells, and as such, the verac-
ity of this proposal does not impact upon our understanding
of hITPK1 function in vivo. However, Ins(1,4,5,6)P4, which
is an intracellular constituent in mammalian cells [15], is one
of the proposed amoeboid ITPK1 substrates that was also
suggested as a substrate for hITPK1. Ins(1,4,5,6)P4 is also
biologically active; it has been shown to regulate Cl trans-
port [16], to be a PtdIns(3,4,5)P3 antagonist [17], and to
bind tightly to some pleckstrin homology domains [18],
and ﬁnally, it may contribute to transcriptional regulation
[19]. Therefore, it is important to understand how the cellu-
lar levels of this inositol phosphate are regulated. If hITPK1
were to participate in maintaining steady-state levels of
Ins(1,4,5,6)P4, then we would need to determine the biolog-
ical impact of competition from other hITPK1 substrates.
In the current study we show that stereochemical factors are
important determinants of ligand speciﬁcity for hITPK1. In so
doing, we show that hITPK1 is not a physiologically relevant
Ins(1,4,5,6)P4 kinase; instead, we show that function is per-
formed by another enzyme, the inositol polyphosphate multi-
kinase.2. Methods
2.1. Materials
Recombinant human ITPK1 (hITPK1) was prepared as previously
described [9,20]. Recombinant human IPMK was prepared as fol-
lows. The cDNA clone IMAGE:4510867 (GenBank2 accession no.
BG258567) was obtained from ATCC. The superﬂuous nucleotide
at position 451 was removed by site-directed mutagenesis, as de-
scribed in Ref. [21]. The open reading frame was completely rese-
quenced. BamHI and KpnI restriction sites were introduced at the
5 0 and 3 0 ends, respectively. Then the cDNA was subcloned into
the pTrcHisA vector and the protein was expressed in Escherichia
coli. Recombinant poly(His)-tagged protein was puriﬁed using Ni-
agarose (Clontech), which was eluted with imidazole according to
the manufacturers instructions.
[3H]Ins(3,4,5,6)P4 and [
3H]Ins(1,4,5,6)P4 were prepared as previ-
ously described (Refs. [20,22], respectively). Non-radiolabeled
Ins(3,4,5,6)P4, Ins(1,4,5,6)P4 and Ins(1,3,4)P3 were purchased from
CellSignals Inc (Lexington, KY). Ins(3,5,6)P3 and Ins(4,5,6)P3 were
synthesized as previously described [23,24] and their identities were
conﬁrmed by 1H, 13C and 31P NMR spectroscopy [23–25]. Previously
unpublished 1H, and 13C NMR data for Ins(4,5,6)P3 are as follows:
1H
NMR (D2O, pH 10) d 3.92 (dd, J = 2.5, 9.3 Hz, 2H, H-1 and H-3), 4.19
(q, J = 9.3 Hz, 1H, H-5), 4.25 (t, J = 2.5 Hz, 1H, H-2), 4.39 (q,
J = 9.3 Hz, 2H, H-4 and H-6); 13C NMR (D2O, pH 10) d 73.87,
74.60 (2C), 78.32 (2C), 79.10.
The purity of Ins(3,5,6)P3 and Ins(4,5,6)P3 was determined by
HPLC separation followed by metal dye detection [26] using two com-
plementary HPLC procedures that employ either an acidic or an alka-
line gradient [27]. In the acidic gradient, Ins(4,5,6)P3 has a unique
elution position that is well-resolved from all other InsP3 isomers
[8,27,28]. Ins(3,5,6)P3 was resolved from other possible InsP3 isomers
by using both gradients [8,11,27,28]. Thus, we were able to show that
Ins(4,5,6)P3 was >97% pure (the approx. 3% contaminant is
Ins(3,4,5)P3; Fig. 2 and see Section 3). Ins(3,5,6)P3 had no detectable
contaminants (Fig. 2 and see Section 3). Finally, this batch of
Ins(3,5,6)P3 has also been shown to be enantiomerically pure (i.e., it
does not contain any Ins(1,4,5)P3) because no inorganic phosphate
was released when Ins(3,5,6)P3 was incubated with Schizosaccharomy-
ces pombe synaptojanin, an active Ins(1,4,5)P3 5-phosphatase [29].
Enantiomeric contamination is not an issue for Ins(4,5,6)P3, which is
a meso-compound.
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Fig. 2. HPLC analysis of the purity of Ins(3,5,6)P3 and Ins(4,5,6)P3.
6 nmol of either Ins(3,5,6)P3 (panel A) or Ins(4,5,6)P3 (panel B) were
analyzed by HPLC using an alkaline gradient (see Section 2 and Ref.
[27]). Isomeric assignments are based on the complementary nature of
the alkaline gradient when used in parallel with an acidic gradient (see
Section 3 and Ref. [27]), which together resolve Ins(3,5,6)P3 and
Ins(4,5,6)P3 from all other InsP3 isomers.
Fig. 3. Two models of the predicted binding and phosphorylation of
Ins(3,5,6)P3, Ins(4,5,6)P3 and Ins(1,4,5,6)P4 by hITPK1. The binding
of inositol phosphates to hITPK1, and the site of phosphorylation
(yellow circle) is predicted according to the model proposed either by
Ho et al. (column a; Ref. [8]) or Miller et al. (column b and Ref. [14]).
N/A, not applicable to this model. See Fig. 1 for the signiﬁcance of
other colour-coding.
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The hITPK1 activity was assayed at 37 C in 100–200 ll buﬀer con-
taining 100 mM KCl, 20 mM HEPES pH 7.2, 5 mM ATP, 10 mM
phosphocreatine, 6 mM MgSO4, 0.3 mg/ml bovine serum albumin
and 3.6 U/ml phosphocreatine kinase (Calbiochem). Other assay de-
tails are given in the ﬁgure legends. Assays with radiolabeled inositol
phosphates were quenched with PCA and neutralized with K2CO3 as
previously described [30]. Some of these assays were analyzed using
gravity-fed ion-exchange columns [30]. Other assays were analyzed
by HPLC using a 12.5 · 4.6 mm Partisphere SAX column (Krackler
Scientiﬁc, NC) as previously described [31]. Kinetic parameters for
IPMK-dependent phosphorylation of [3H]Ins(1,4,5,6)P4 were deter-
mined with assays that contained a range of Ins(1,4,5,6)P4 concentra-
tions from 0.05 to 1.8 lM. Km and Vmax were determined as previously
described [32], by non-linear curve ﬁtting to the Michaelis–Menten
equation, using SigmaPlot. Other assays that consisted entirely of
non-radiolabeled inositol phosphates were quenched by boiling for
3 min, and then processed for analysis by HPLC separation followed
by metal dye detection [26] using an acidic gradient as described by
Adelt et al. [27]. Data were exported as ASCII ﬁles into SigmaPlot.3. Results and discussion
3.1. Is Ins(3,5,6)P3 a substrate of hITPK1?
Ins(3,5,6)P3 is not a physiologically relevant inositol phos-
phate, but it has been utilized in the current study to provide
useful information on the regioselectivity of human ITPK1
(hITPK1). Our model predicts that Ins(3,5,6)P3 is a candidate
mode 1 substrate, and, therefore, it would only be phosphory-
lated at the 1-position (column a, Fig. 3). An alternative model
of the activities of mammalian ITPK1 predicts that it will
phosphorylate either (although not both) of the 1- and 2-
hydroxyls of Ins(3,5,6)P3 (column b in Fig. 3); the latter pre-
diction is based on a structural characterization of an ITPK1
homologue from E. histolytica [14].
We tested these diﬀerent ideas concerning positional speciﬁc-
ity of hITPK1 using non-radiolabeled Ins(3,5,6)P3, the metab-
olism of which was recorded using an on-line mass-detection
HPLC technique [26,27]. As a control, we also recorded the
phosphorylation of non-radiolabeled Ins(1,3,4)P3 (Fig. 4). It
should be noted that the sensitivity of this method increases
when there are a larger number of phosphate groups around
the inositol ring [26]. For example, an InsP4 will yield a larger
signal than an equivalent concentration of InsP3 [26]. This
technical point is apparent following an analysis of
Ins(1,3,4)P3 phosphorylation by ITPK1; the sizes of the peaks
of the two products (Ins(1,3,4,5)P4 and Ins(1,3,4,6)P4) are lar-
ger than the peak of the original substrate (Fig. 4A).
There have been eﬀorts to rationalize why two InsP4 isomers
are formed upon phosphorylation of Ins(1,3,4)P3 by ITPK1.
At least for the ITPK1 homologue in E. histolytica, Miller
et al. [14] have proposed that the phosphorylation of
Ins(1,3,4)P3 at both the 5- and 6-hydroxyl is possible in one
substrate-binding mode. Both of these hydroxyl groups are
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Fig. 4. HPLC Analysis of the phosphorylation of Ins(1,3,4)P3 and
Ins(3,5,6)P3 by hITPK1. Recombinant hITPK1 (3400 ng) was incu-
bated in 200 ll assay buﬀer for 0 (dotted trace) or 4 h (solid trace) with
50 lM of either Ins(1,3,4)P3 (panel A) or Ins(3,5,6)P3 (panel B) as
described in Section 2. Samples were quenched by boiling and analyzed
by an on-line mass detection HPLC technique that uses an acidic
gradient (see Section 2). The absorbance at the 30 min elution time was
arbitrarily set to zero. The elution positions of the named InsP4
isomers are arrowed; these were determined using genuine standards
[11]. Note that sensitivity of this technique depends upon the number
of phosphate groups; thus, an InsP4 yields a larger signal than an
equivalent concentration of InsP3 [26,27].
A.M. Riley et al. / FEBS Letters 580 (2006) 324–330 327suﬃciently close to the c-phosphate of ATP that either (but
not both) can, in principle, be phosphorylated by direct inline
transfer. The latter proposal is distinct from our earlier
hypothesis that mammalian ITPK1 has two binding modes
for Ins(1,3,4)P3, which separately determine whether it is the
5-hydroxyl or the 6-hydroxyl that is phosphorylated [8]. None
of the new data that are presented in the current study are able
to distinguish between these two alternate models.
In agreement with the prediction of Miller et al. [14], we
found that Ins(3,5,6)P3 was phosphorylated by hITPK1
(Fig. 4B). A single InsP4 product was identiﬁed which co-
eluted with standards of Ins(1,3,5,6)P4. No InsP5 was formed
from Ins(1,3,5,6)P4 (data not shown). More importantly, no
product accumulated with the retention times of Ins(2,3,5,6)P4
or Ins(3,4,5,6)P4 (Fig. 4B). These data are in agreement with
our stereochemically based model for ligand binding, which
does not permit phosphorylation of either the 2- or 4-hydrox-yls of Ins(3,5,6)P3 (Fig. 4). Clearly, the stereochemistry of the
inositol ring at C-2 prevents phosphorylation of the 2-OH
group by hITPK1 in both Ins(3,4,5,6)P4 and Ins(3,5,6)P3,
either by dictating possible binding modes, and/or because
an axial hydroxyl group cannot be presented to the active site
in the correct orientation for phosphoryl transfer.
According to our model of ligand binding (Fig. 3, column
a), regioselective phosphorylation of Ins(3,5,6)P3 at the
1-position characterizes it as a mode 1 substrate. Since
Ins(3,4,5,6)P4 is also a mode 1 substrate (Fig. 1), we deter-
mined the aﬃnity of hITPK1 for Ins(3,5,6)P3 to quantify the
contribution of the 4-phosphate to ligand binding. We consid-
ered this to be an important experiment because the 4-phos-
phate of Ins(3,4,5,6)P4 is not one of those groups that has an
equivalent in all three of our proposed ligand-binding modes
(Figs. 1 and 3). Therefore, this situation gave us an opportu-
nity to test our combinatorial hypothesis that the 4-phosphate
might be one of those determinants of ligand binding that are
mode-speciﬁc.
The value of the IC50 with which Ins(3,5,6)P3 inhibited
Ins(3,4,5,6)P4 phosphorylation was used to calculate the aﬃn-
ity of the inhibitor (Fig. 5). As a control, we also checked the
aﬃnity for Ins(1,3,4)P3 using the same method (Fig. 5). As ex-
pected, Ins(1,3,4)P3 potently inhibited hITPK1 activity to-
wards Ins(3,4,5,6)P4 (IC50 = 7.6 lM; Ki = 0.15 lM, Fig. 5A).
This method for measuring substrate aﬃnity is validated by
the estimated aﬃnity of Ins(1,3,4)P3 being very close to the
previously determined Km value (0.3 lM; Ref. [9]). The aﬃnity
of Ins(3,5,6)P3 for hITPK1 (IC50 = 100 lM; Ki = 2 lM;
Fig. 5B) is around 13-fold lower than that for Ins(3,4,5,6)P4
(0.1 lM, Ref. [9]). In other words, removal of the 4-phosphate
from Ins(3,4,5,6)P4 can be concluded to reduce ligand aﬃnity
13-fold. The 4-phosphate has this function in mode 1, and
there is a surrogate in mode 2 (Fig. 1). There is not an equiv-
alent group in mode 3 (Fig. 1). Thus, the 4-phosphate in
Ins(3,4,5,6)P4 may be one of those groups that we have
proposed makes a contribution to ligand binding in a mode-
speciﬁc manner.
3.2. Is Ins(1,4,5,6)P4 a substrate of hITPK1?
Ins(1,4,5,6)P4 is another inositol phosphate that can distin-
guish between the two diﬀerent models of ligand binding de-
scribed in Figs. 1 and 3. In our model, this inositol
phosphate is not predicted to be a substrate, as it cannot pres-
ent the key recognition features to the active site in any of our
three binding modes. In contrast, Miller et al. [14] consider
Ins(1,4,5,6)P4 to be a potential substrate of hITPK1, based
on their model of the amoeboid homologue, because
Ins(1,4,5,6)P4 contains three appropriately positioned phos-
phate groups, but this would only be valid if stereochemical
factors are not signiﬁcant determinants of ligand speciﬁcity
(Figs. 1 and 3). The resolution of this issue has physiological
relevance because Ins(1,4,5,6)P4 is proposed to be a biologi-
cally active constituent of mammalian cells (see Section 1). It
is therefore an important goal to understand the nature of
the enzymes that metabolize Ins(1,4,5,6)P4 in vivo.
In order to maximize the sensitivity of these kinase assays, we
incubated hITPK1 with [3H]Ins(1,4,5,6)P4, and we measured its
ability to be metabolized under ﬁrst-order conditions. There
was no phosphorylation (Fig. 6A). In contrast, 42% of added
[3H]Ins(3,4,5,6)P4 was phosphorylated by a concentration of
hITPK1 (Fig. 6B) that was approx. 1600-fold lower than that
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Fig. 5. Determination of the aﬃnity of Ins(1,3,4)P3 and Ins(3,5,6)P3
for hITPK1. Recombinant hITPK1 (24 ng) was incubated in 100 ll
assay buﬀer for 30 min with 5 lM [3H]Ins(3,4,5,6)P4 as described in
Section 2, plus the indicated concentrations of either Ins(1,3,4)P3
(panel A) or Ins(3,5,6)P3 (panel B). Samples were acid quenched,
neutralized, and analyzed by gravity-fed columns as described in
Section 2. Data shown are from a representative experiment performed
in duplicate (typical of three). Ki values were estimated from the
empirically determined IC50 value using the following equation:
Ki = (IC50 · Km)/([S] + Km); [S], substrate concentration and the value
of the Km for Ins(3,4,5,6)P4 is 0.1 lM [9].
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Assays were performed for 10 min in 100 ll assay buﬀer as described in
Section 2 with either (panel A) 800 D.P.M. [3H]Ins(1,4,5,6)P4 plus
7500 ng hITPK1, or (panel B) 2500 D.P.M. [3H]Ins(3,4,5,6)P4 plus
4.8 ng hITPK1, or (panel C) 800 D.P.M. [3H]Ins(1,4,5,6)P4 plus 53 ng
hIPMK.Assayswere acid quenched, neutralized and analyzedbyHPLC
as described in Section 2.
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5% phosphorylation as a conservative estimate of the minimal
level of detection, we can calculate that we would have been
able to measure any Ins(1,4,5,6)P4 phosphorylation that oc-
curred at a rate that was up to 13,000-fold slower than that
of Ins(3,4,5,6)P4. We therefore conclude that Ins(1,4,5,6)P4 is
not a physiologically relevant hITPK1 substrate. This diﬀer-
ence in the reactivity of hITPK1 towards Ins(3,4,5,6)P4 vs.
Ins(1,4,5,6)P4 is particularly pertinent to the current study be-
cause these two compounds are enantiomers; our data
(Fig. 6) therefore again verify that stereochemistry is an impor-
tant determinant of the substrate speciﬁcity of hITPK1.
While hITPK1 cannot phosphorylate Ins(1,4,5,6)P4, there is
an enzyme that was previously observed in mammalian cell ly-
sates that does show Ins(1,4,5,6)P4 3-kinase activity [15,33,34].
Majerus and colleagues [32] have proposed that this mamma-
lian 3-kinase activity is performed by IPMK (also known as
IPK2). In support of this idea, the latter group heterologously
overexpressed rat IPMK in a strain of S. cerevisiae that lacksthe inherent ability to phosphorylate Ins(1,4,5,6)P4 to InsP5; in
these yeast cells, rat IPMK rescued InsP5 synthesis [32]. We
have provided support to the latter observations by demon-
strating that Ins(1,4,5,6)P4 is phosphorylated by puriﬁed re-
combinant human IPMK (Fig. 6C). Moreover, the kinetic
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A.M. Riley et al. / FEBS Letters 580 (2006) 324–330 329parameters that we determined for this Ins(1,4,5,6)P4 3-kinase
activity (Km = 0.18 lM; Vmax = 139 nmol/mg protein/min) are
similar to those for its other substrates [21,32]. These experi-
ments also verify the nature of the [3H]Ins(1,4,5,6)P4 substrate
used in the experiment described in Fig. 6A.B
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503.3. Is Ins(4,5,6)P3 a substrate of hITPK1?
Ins(4,5,6)P3 is not a physiologically relevant inositol phos-
phate in mammalian cells. However, it is useful for studying
the importance of ring stereochemistry in determining sub-
strate speciﬁcity, because it is a meso-compound, i.e., a plane
of symmetry runs through the ring (between the 2- and 5-posi-
tions). We found Ins(4,5,6)P3 to have only weak aﬃnity for
hITPK1; 200 lM Ins(4,5,6)P3 inhibited Ins(3,4,5,6)P4 phos-
phorylation by only 25% (Fig. 7A). Nevertheless, Ins(4,5,6)P3
was phosphorylated by hITPK1 (Fig. 7B). A single InsP4 peak
was detected, at the elution position of the Ins(3,4,5,6)P4/
Ins(1,4,5,6)P4 enantiomeric pair. Since the InsP4 was not fur-
ther phosphorylated to InsP5, we conclude the InsP4 is
Ins(1,4,5,6)P4, since that is not a physiological substrate of
hITPK1 (Fig. 6).
Despite Ins(4,5,6)P3 being a meso-compound, our data re-
veal that hITPK1 shows a preference for phosphorylating
the 1-hydroxyl rather than the 3-hydroxyl. Thus, hITPK1
can clearly distinguish between enantiotopic groups in this
substrate. This result oﬀers further testimony to the stereo-
chemical preferences of this enzyme.Elution time (min)
28 32 36 40 44 48 52 56
0.0
Fig. 7. Ins(4,5,6)P3 is regioselectively phosphorylated by hITPK1.
Panel A. Recombinant hITPK1 (24 ng) was incubated in 100 ll assay
buﬀer for 30 min with 5 lM [3H]Ins(3,4,5,6)P4 as described in Section
2, plus the indicated concentrations of Ins(4,5,6)P3. Samples were acid
quenched, neutralized, and analyzed by gravity-fed columns as
described in Section 2. Data shown are from a representative
experiment performed in duplicate (typical of three). Panel B.
Recombinant hITPK1 (3400 ng) was incubated in 200 ll assay buﬀer
for 0 (dotted trace) or 4 h (solid trace) with 50 lM of Ins(4,5,6)P3 as
described in Section 2. Samples were quenched by boiling and analyzed
by an on-line mass detection HPLC technique that uses an acidic
gradient (see Section 2). The absorbance at the 30 min elution time was
arbitrarily set to zero. Note that a small contaminant that was not
metabolized eluted 2 min prior to Ins(4,5,6)P3; the contaminant is
Ins(3,4,5)P3 (see text and Fig. 2). The elution positions of the named
InsP4 isomers are arrowed; these were determined using genuine
standards [11].3.4. Concluding comments
The structural characterization of the ITPK1 from E. his-
tolytica led to the generation of a model of the active site in
which the hydroxyl groups, and their orientation, and the ste-
reochemical properties of the molecule, all do not contribute
signiﬁcantly to substrate speciﬁcity [14]. It was further pro-
posed that the model could be applied to mammalian ITPK1
[14]. An investigation of the latter proposal was one of the
goals of the current study. We have used three diﬀerent inositol
phosphates to show that, in each case, hITPK1 recognizes the
stereochemistry of its substrates at key positions around the
inositol ring, including the hydroxyl groups. Miller et al. [14]
have further suggested that hITPK1 mimics the ability of
ITPK1 from E. histolytica to phosphorylate either of two adja-
cent hydroxyls on a single substrate, even if one of these hydro-
xyl groups is axial to the plane of the inositol ring. Our new
data (Figs. 4 and 7) indicate that hITPK1 can only phosphor-
ylate a single, equatorial hydroxyl on either Ins(3,5,6)P3 or
Ins(4,5,6)P3. The same is true of Ins(3,4,5,6)P4 [9]. It seems that
evolutionary pressure has narrowed the substrate speciﬁcity of
the mammalian enzyme [14,35]. For example, the human en-
zyme has lost the ability to phosphorylate Ins(1,4,5)P3, which
is a notable characteristic of ITPK1 from E. histolytica [14,35].
This diﬀerence may be attributed to Ser-295 in the amoeboid
enzyme being replaced by a glycine residue in hITPK1 [14].
Our studies not only advance our insight into the nature of
the active site of mammalian ITPK1, but they also increase our
understanding of the metabolism of Ins(1,4,5,6)P4, which is
reportedly a biologically active constituent of eukaryotic cells
[16,17,19]. Our data demonstrate that it is IPMK, and not
ITPK1, that has the capacity to regulate the cellular levels of
Ins(1,4,5,6)P4 in mammalian cells. This conclusion should as-
sist our understanding of the cell biology of Ins(1,4,5,6)P4.Acknowledgements: We thank the Wellcome Trust for Programme
Grant Support (060554 to BVLP). This research was also supported
by the Intramural Research Program of the NIH, National Institute
of Environmental Health Sciences.References
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